The wound care management market comprises of dressings, equipment and other aids to prevent and treat wounds and quicken or promote wound healing. Tissue engineering for wound care management is the use of mechanical and chemical processing of materials to manufacture products that may substitute or replace all or some components that make up a normal skin (e.g. , epidermis and/or dermis, cells, and matrix). GlobalData uses proprietary data and analytics to provide a comprehensive report on the tissue engineered – skin substitutes devices market, including market shares of different players within Australia. Buy the latest report here.
Smarter leaders trust GlobalData
In 2022, GlobalData’s Market Model methodology determined that the leading player in the tissue engineered – skin substitutes market in Australia was Allergan followed by Integra LifeSciences, Smith & Nephew and LifeNet Health.
Tissue Engineered Skin Substitutes can be derived from human tissue (autologous or allogenic), non-human tissue (enographic), a composite, or synthetic materials. Acellular or cellular may consist of a synthetic epidermis and a collagen-based dermis to encourage formation of new tissue. In products that have a synthetic epidermis, this may be a temporary wound covering. This category consists of cellular skin substitutes and acellular skin substitutes.
Following the widespread disruption resulting from the COVID-19 pandemic to the broader medical devices market during 2020 and 2021, the value of the tissue engineered – skin substitutes devices market within Australia was expected to be over $20m in 2022.
For the latest complete market share analysis of tissue engineered – skin substitutes device market in Australia, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
